glp-1 obesity drugs pipeline A Beginner's Guide to Investing in Weight Loss Market Overview: GLP-1 Agonists and
Description
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP
J Hypertens 2006;24:11871192
Xu J, Wang S, Wu H, Chen D, Han J, Lin Q
In subsequent Phase 2 trials, once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 8 mg, and 12 mg resulted in marked improvements in glycemic control compared to placebo, along with substantial weight loss when contrasted with placebo and dulaglutide (1.5 mg)
The posterior upper arm works but is harder to self-administer
The finished compounded product is not reviewed or approved by the FDA
